Page 158 - SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA

Serbian Association for Cancer Research SDIRSACR

most active derivatives (TNT403, TNT404, TNT405 and TNT406), were studied further for activity against two human
pancreatic cancer cell lines: PANC-1 and EANM-ATT021013 (patient-derived cells). Wound healing assay at different
concentrations and time intervals was performed to study the ability of these substances to inhibit cell migration.
For the ability of the substances to inhibit the formation of colonies by single cells, clonogenic experiments were
performed.
Results: 15 out of the 20 substances tested showed strong inhibitory activity (GI50< 6μM). Out of the six substances
tested in pancreatic cancer, TNT404 showed the strongest antiproliferative activity against PANC-1 (GI50 = 0.3μM). In
the wound healing assay, TNT404 was found to strongly inhibit cell migration in a time- and dose-dependent manner,
as well as the formation of PANC-1 colonies.
Conclusions: All 20 semisynthetic derivatives of sclareol with 1,2,4-triazolo[1,5-a]pyrimidines, tested for the first time
for their in vitro anticancer activity against six different human cancer cell lines, including a patient-derived PDAC cell
population, showed significant anticancer activity. Further research into their mechanism of action is underway in our
laboratories.

P68

Exploring the therapeutic potential of Geum urbanum in glioblastoma: in vitro evaluation on U87 and
LN229 cells

Simona Lapčević , Tanja Stojadinović , Mladen Rajaković , Danijela Drakulić , Dejan Stojković , Danijela Stanisavljević
1
2
1
1
2
Ninković 1
1Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia
2Institute for Biological Research "Siniša Stanković", University of Belgrade, Belgrade, Serbia
Keywords: anticancer drugs, Geum urbanum, glioblastoma

Background: Glioblastoma represents 49% of malignant brain tumors and is the most common and aggressive type
of brain cancer. Current therapy for this malignant brain is surgery, followed by radiotherapy and chemotherapy, and
even though its aggressive, prognoses for survival of patients with glioblastoma are poor with high mortality rates.
One of the unwanted and limiting features of glioblastoma is resistance to therapy. Finding drugs or molecules that can
overcome this restrain is crucial for developing more effective glioblastoma treatments. Natural compounds derived
from plants have potential as drugs for the treatment of glioblastoma and are considered as potential anticancer drugs.
Geum urbanum belongs to the genus Geum, which is characterized by the presence of bioactive compounds with
known anticancer potential. Our aim was to analyze the effect of G. urbanum extracts on glioblastoma cells.
Material and Methods: Four extracts were isolated from G. urbanum and were used for treatment of human
glioblastoma cell lines U87 and LN229. 24h after treatment, cytotoxicity of these extracts was studied using MTT
assay and microscopy. In addition, we tested the effect of these extracts on U87 sphere viability using Calcein-AM and
propidium iodide staining.
Results: Obtained results show that G. urbanum extracts show significant cytotoxic effect on LN229 cell line, while no
cytotoxicity was observed on U87 cell line. Microscopic visualization of cells treated with G. urbanum extracts revealed
induction of sphere formation in U87 cells, but no morphological changes in LN229 cells. Measurement of sphere
viability indicated that G. urbanum extracts had no effect on sphere viability in U87 cells.
Conclusions: Our results indicate that G. urbanum extracts exhibit selective cytotoxic effects on glioblastoma cells,
significantly impacting LN229 cells, while demonstrating no cytotoxicity on U87 cells. Interestingly, the extracts
promoted sphere formation in U87 cells without affecting their viability, suggesting a possible role in modulating cell
behavior rather than inducing cell death in this line. These findings highlight the potential of G. urbanum as a source
of bioactive compounds with differential effects on glioblastoma subtypes and support further investigation into its
mechanisms of action and therapeutic relevance in glioblastoma treatment.

143